journal
MENU ▼
Read by QxMD icon Read
search

PharmacoEconomics

journal
https://www.readbyqxmd.com/read/28795341/adjuvant-trastuzumab-therapy-for-early-her2-positive-breast-cancer-in-iran-a-cost-effectiveness-and-scenario-analysis-for-an-optimal-treatment-strategy
#1
Amir Ansaripour, Carin A Uyl-de Groot, W Ken Redekop
INTRODUCTION: Clinical guidelines have recommended a 1-year trastuzumab regimen as standard care for early human epidermal growth factor receptor 2 (HER2)-positive breast cancer; however, this recommendation can have a dramatic impact on total drug expenditures in middle-income countries (MICs). We performed a cost-effectiveness analysis from the Iranian healthcare perspective to find an optimum duration of trastuzumab use in Iran. METHOD: We compared four treatment strategies comprising chemotherapy and varying durations of trastuzumab use (no trastuzumab, 6, 9 months, and 1 year), and a Markov model and probabilistic sensitivity analysis were used to estimate the costs and effects of the strategies...
August 9, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28791663/icer-s-revised-value-assessment-framework-for-2017-2019-a-critique
#2
LETTER
Peter J Neumann, Joshua T Cohen
No abstract text is available yet for this article.
August 8, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28776320/cost-effectiveness-of-support-for-people-starting-a-new-medication-for-a-long-term-condition-through-community-pharmacies-an-economic-evaluation-of-the-new-medicine-service-nms-compared-with-normal-practice
#3
Rachel A Elliott, Lukasz Tanajewski, Georgios Gkountouras, Anthony J Avery, Nick Barber, Rajnikant Mehta, Matthew J Boyd, Asam Latif, Antony Chuter, Justin Waring
BACKGROUND: The English community pharmacy New Medicine Service (NMS) significantly increases patient adherence to medicines, compared with normal practice. We examined the cost effectiveness of NMS compared with normal practice by combining adherence improvement and intervention costs with the effect of increased adherence on patient outcomes and healthcare costs. METHODS: We developed Markov models for diseases targeted by the NMS (hypertension, type 2 diabetes mellitus, chronic obstructive pulmonary disease, asthma and antiplatelet regimens) to assess the impact of patients' non-adherence...
August 3, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28770453/examining-the-feasibility-and-utility-of-estimating-partial-expected-value-of-perfect-information-via-a-nonparametric-approach-as-part-of-the-reimbursement-decision-making-process-in-ireland-application-to-drugs-for-cancer
#4
Laura McCullagh, Susanne Schmitz, Michael Barry, Cathal Walsh
BACKGROUND: In Ireland, all new drugs for which reimbursement by the healthcare payer is sought undergo a health technology assessment by the National Centre for Pharmacoeconomics. The National Centre for Pharmacoeconomics estimate expected value of perfect information but not partial expected value of perfect information (owing to computational expense associated with typical methodologies). OBJECTIVE: The objective of this study was to examine the feasibility and utility of estimating partial expected value of perfect information via a computationally efficient, non-parametric regression approach...
August 2, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28770452/pertuzumab-for-the-neoadjuvant-treatment-of-early-stage-her2-positive-breast-cancer-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#5
REVIEW
Hazel Squires, Abdullah Pandor, Praveen Thokala, John W Stevens, Eva Kaltenthaler, Mark Clowes, Robert Coleman, Lynda Wyld
As part of its single technology appraisal process, the National Institute for Health and Care Excellence invited the manufacturer of pertuzumab (Perjeta(®); Roche Products Limited) to submit evidence of its clinical and cost- effectiveness for the neoadjuvant treatment of women with high-risk, early-stage, HER2-positive breast cancer when used in combination with trastuzumab and chemotherapy. High-risk women included those with locally advanced (including inflammatory) breast cancer and women with high-risk early-stage breast cancer (classified as T2/3 or N1)...
August 2, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28762015/using-genomic-information-to-guide-ibrutinib-treatment-decisions-in-chronic-lymphocytic-leukaemia-a-cost-effectiveness-analysis
#6
James Buchanan, Sarah Wordsworth, Ruth Clifford, Pauline Robbe, Jenny C Taylor, Anna Schuh, Samantha J L Knight
BACKGROUND: Genomic tests may improve the stratification of patients to receive new therapies in several disease areas. However, the use of expensive targeted therapies can impact on the cost effectiveness of these tests. This study presents an economic evaluation of genomic testing in chronic lymphocytic leukaemia in the context of the UK National Health Service. METHODS: Cost-effectiveness and cost-utility analyses (using life-years and quality-adjusted life-years) were undertaken from a National Health Service and societal perspective...
July 31, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28756597/treatments-for-metastatic-prostate-cancer-mpc-a-review-of-costing-evidence
#7
REVIEW
Jan Norum, Carsten Nieder
BACKGROUND: Prostate cancer (PC) is the most common cancer in Western countries. More than one third of PC patients develop metastatic disease, and the 5-year expected survival in distant disease is about 35%. During the last few years, new treatments have been launched for metastatic castrate-resistant prostate cancer (mCRPC). OBJECTIVES: We aimed to review the current literature on health economic analysis on the treatment of metastatic prostate cancer (mPC), compare the studies, summarize the findings and make the results available to administrators and decision makers...
July 29, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28748450/replicating-health-economic-models-firm-foundations-or-a-house-of-cards
#8
Inigo Bermejo, Paul Tappenden, Ji-Hee Youn
Health economic evaluation is a framework for the comparative analysis of the incremental health gains and costs associated with competing decision alternatives. The process of developing health economic models is usually complex, financially expensive and time-consuming. For these reasons, model development is sometimes based on previous model-based analyses; this endeavour is usually referred to as model replication. Such model replication activity may involve the comprehensive reproduction of an existing model or 'borrowing' all or part of a previously developed model structure...
July 26, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28710740/mapping-promis-global-health-items-to-euroqol-eq-5d-utility-scores-using-linear-and-equipercentile-equating
#9
Nicolas R Thompson, Brittany R Lapin, Irene L Katzan
BACKGROUND: Mapping Patient-Reported Outcomes Measurement Information System-Global Health (PROMIS-GH) to EuroQol 5-dimension, three-level version (EQ-5D-3L) provides a utility score for use in quality-of-life and cost-effectiveness analyses. In 2009, Revicki et al. mapped the PROMIS-GH items to EQ-5D-3L utilities using linear regression (REVReg). More recently, regression was shown to be ill-suited for mapping to preference-based measures due to regression to the mean. Linear and equipercentile equating are alternative mapping methods that avoid the issue of regression to the mean...
July 14, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28699086/estimating-direct-cost-of-cystic-fibrosis-care-using-irish-registry-healthcare-resource-utilisation-data-2008-2012
#10
Abaigeal D Jackson, Andrew L Jackson, Godfrey Fletcher, Gerardine Doyle, Mary Harrington, Shijun Zhou, Fiona Cullinane, Charles Gallagher, Edward McKone
BACKGROUND: Understanding the determinants of cost of cystic fibrosis (CF) care and health outcomes may be useful for financial planning for the delivery of CF services. Registries contain information otherwise unavailable to healthcare activity/cost monitoring systems. We estimated the direct medical cost of CF care using registry data and examined how cost was affected by patient characteristics and CF gene (CF Transmembrane Conductance Regulator [CFTR]) mutation. METHODS: Healthcare resource utilisation data (2008-2012) were obtained for CF patients enrolled with the Irish CF Registry by 2013 from linked registry and national hospitalisation database records...
July 11, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28695544/performance-based-risk-sharing-arrangements-an-updated-international-review
#11
REVIEW
Josh J Carlson, Shuxian Chen, Louis P Garrison
Enthusiasm for performance-based risk-sharing arrangements (PBRSAs) continues but at variable pace across countries. Our objective was to identify and characterize publicly available cases and related trends for these arrangements. We performed a review of PBRSAs from 1993 to 2016 using the University of Washington PBRSA Database. Arrangements were categorized according to a previously published taxonomy. Macro-level trends were identified related to the timing of adoption, countries involved, types of arrangements, and disease areas...
July 10, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28695543/the-indonesian-eq-5d-5l-value-set
#12
Fredrick Dermawan Purba, Joke A M Hunfeld, Aulia Iskandarsyah, Titi Sahidah Fitriana, Sawitri Supardi Sadarjoen, Juan Manuel Ramos-Goñi, Jan Passchier, Jan J V Busschbach
BACKGROUND: The EQ-5D is one of the most used generic health-related quality-of-life (HRQOL) instruments worldwide. To make the EQ-5D suitable for use in economic evaluations, a societal-based value set is needed. Indonesia does not have such a value set. OBJECTIVE: The aim of this study was to derive an EQ-5D-5L value set from the Indonesian general population. METHODS: A representative sample aged 17 years and over was recruited from the Indonesian general population...
July 10, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28681277/availability-and-pricing-new-medicines-in-ireland-reflections-and-reform
#13
Paul K Gorecki
This paper argues that the current method of determining the availability and pricing of new medicines for public reimbursement in Ireland likely results in too large a share of public healthcare expenditure allocated to medicines. Resources are misallocated. Welfare is lowered. In contrast to some other areas of public healthcare, patients exercise 'voice' rather than 'exit' concerning the public provision of high-cost new medicines. Setting publicly agreed cost-effectiveness thresholds, with clear predictable criteria for when the cost-effectiveness thresholds can be exceeded, would contribute to the creation of a more appropriate new medicine decision-making framework...
July 5, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28674846/reporting-and-analysis-of-trial-based-cost-effectiveness-evaluations-in-obstetrics-and-gynaecology
#14
REVIEW
Mohamed El Alili, Johanna M van Dongen, Judith A F Huirne, Maurits W van Tulder, Judith E Bosmans
BACKGROUND AND OBJECTIVES: The aim was to systematically review whether the reporting and analysis of trial-based cost-effectiveness evaluations in the field of obstetrics and gynaecology comply with guidelines and recommendations, and whether this has improved over time. DATA SOURCES AND SELECTION CRITERIA: A literature search was performed in MEDLINE, the NHS Economic Evaluation Database (NHS EED) and the Health Technology Assessment (HTA) database to identify trial-based cost-effectiveness evaluations in obstetrics and gynaecology published between January 1, 2000 and May 16, 2017...
July 3, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28674845/discrete-event-simulation-based-resource-modelling-in-health-technology-assessment
#15
REVIEW
Syed Salleh, Praveen Thokala, Alan Brennan, Ruby Hughes, Simon Dixon
OBJECTIVE: The objective of this article was to conduct a systematic review of published research on the use of discrete event simulation (DES) for resource modelling (RM) in health technology assessment (HTA). RM is broadly defined as incorporating and measuring effects of constraints on physical resources (e.g. beds, doctors, nurses) in HTA models. METHODS: Systematic literature searches were conducted in academic databases (JSTOR, SAGE, SPRINGER, SCOPUS, IEEE, Science Direct, PubMed, EMBASE) and grey literature (Google Scholar, NHS journal library), enhanced by manual searchers (i...
July 3, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28669122/validation-of-a-dice-simulation-against-a-discrete-event-simulation-implemented-entirely-in-code
#16
Jörgen Möller, Sarah Davis, Matt Stevenson, J Jaime Caro
BACKGROUND: Modeling is an essential tool for health technology assessment, and various techniques for conceptualizing and implementing such models have been described. Recently, a new method has been proposed-the discretely integrated condition event or DICE simulation-that enables frequently employed approaches to be specified using a common, simple structure that can be entirely contained and executed within widely available spreadsheet software. To assess if a DICE simulation provides equivalent results to an existing discrete event simulation, a comparison was undertaken...
July 1, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28660474/ahead-of-our-time-collaboration-in-modeling-then-and-now
#17
LETTER
Renée J G Arnold, Sean Ekins
No abstract text is available yet for this article.
June 28, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28660473/assessing-the-value-of-biosimilars-a-review-of-the-role-of-budget-impact-analysis
#18
REVIEW
Steven Simoens, Ira Jacobs, Robert Popovian, Leah Isakov, Lesley G Shane
Biosimilar drugs are highly similar to an originator (reference) biologic, with no clinically meaningful differences in terms of safety or efficacy. As biosimilars offer the potential for lower acquisition costs versus the originator biologic, evaluating the economic implications of the introduction of biosimilars is of interest. Budget impact analysis (BIA) is a commonly used methodology. This review of published BIAs of biosimilar fusion proteins and/or monoclonal antibodies identified 12 unique publications (three full papers and nine congress posters)...
June 28, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28656543/ramucirumab-for-treating-advanced-gastric-cancer-or-gastro-oesophageal-junction-adenocarcinoma-previously-treated-with-chemotherapy-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#19
REVIEW
Nasuh C Büyükkaramikli, Hedwig M Blommestein, Rob Riemsma, Nigel Armstrong, Fiona J Clay, Janine Ross, Gill Worthy, Johan Severens, Jos Kleijnen, Maiwenn J Al
The National Institute for Health and Care Excellence (NICE) invited the company that manufactures ramucirumab (Cyramza(®), Eli Lilly and Company) to submit evidence of the clinical and cost effectiveness of the drug administered alone (monotherapy) or with paclitaxel (combination therapy) for treating adults with advanced gastric cancer or gastro-oesophageal junction (GC/GOJ) adenocarcinoma that were previously treated with chemotherapy, as part of the Institute's single technology appraisal (STA) process...
June 27, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28631197/prioritizing-future-research-on-allopurinol-and-febuxostat-for-the-management-of-gout-value-of-information-analysis
#20
Eric Jutkowitz, Fernando Alarid-Escudero, Hyon K Choi, Karen M Kuntz, Hawre Jalal
OBJECTIVES: The aim of this study was to quantify the value of conducting additional research and reducing uncertainty regarding the cost effectiveness of allopurinol and febuxostat for the management of gout. METHODS: We used a previously developed Markov model that evaluated the cost effectiveness of nine urate-lowering strategies: no treatment, allopurinol-only fixed dose (300 mg), allopurinol-only dose escalation (up to 800 mg), febuxostat-only fixed dose (80 mg), febuxostat-only dose escalation (up to 120 mg), allopurinol-febuxostat sequential therapy fixed dose, allopurinol-febuxostat sequential therapy dose escalation, febuxostat-allopurinol sequential therapy fixed dose, and febuxostat-allopurinol sequential therapy dose escalation...
June 19, 2017: PharmacoEconomics
journal
journal
31126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"